HHMI
ESPR

Howard Hughes Medical Institute’s Esperion Therapeutics ESPR Stock Holding History

Howard Hughes Medical Institute’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,770
Closed -$42K – 178
2015
Q3 		$42K Buy
1,770
+1,570
+785% +$98.5K 0.01% 149
2015
Q2 		$16K Buy
+200
New +$19.6K ﹤0.01% 158

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Howard Hughes Medical Institute's ESPR Position: Q4 2015 in Review

Howard Hughes Medical Institute sold out of Esperion Therapeutics (ESPR) in Q4 2015, closing a stake of 1,770 shares — an estimated $42K sold.

Howard Hughes Medical Institute first reported a position in ESPR in Q2 2015 and held it in 2 quarters. The position peaked at $42K in Q3 2015. 113 funds tracked by Wall St. Rank hold ESPR as of Q4 2015.

  • Howard Hughes Medical Institute reported no remaining Esperion Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Howard Hughes Medical Institute sold 1,770 Esperion Therapeutics shares in Q4 2015, an estimated $42K.
  • Howard Hughes Medical Institute first reported a position in Esperion Therapeutics in Q2 2015 and held it in 2 quarters.
  • Howard Hughes Medical Institute's Esperion Therapeutics position peaked at $42K in Q3 2015.
  • 113 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2015.

Based on Howard Hughes Medical Institute's 13F filing for Q4 2015, filed 11 Feb 2016.